APELOA has obtained FDA approval for Amantadine Hydrochloride Tablets (100mg), following the approval of Metoprolol Succinate Extended-Release Tablets in July—another significant step in our global expansion.

Amantadine, originally approved in 1966 for flu prevention and later in 1973 for Parkinson's disease, works by increasing dopamine synthesis and release while reducing reuptake. It also acts as an NMDA receptor antagonist, protecting neurons and improving both Parkinson’s symptoms and movement complications.

APELOA remains committed to providing high-quality, safe medications to patients worldwide, to enable global clients in expediting the delivery of affordable medications.